Therefore, a large-scale, multivariate evaluation of Anti-TPO’s impact on AMH, AFC, and FSH across age, BMI, and PCOS subgroups is critically needed to guide early fertility assessment and targeted clinical interventions. Here, TPO is linked to polycystic ovary syndrome.